BioCentury
ARTICLE | Product Development

Surrogate start

What Probiodrug’s Phase IIa results suggest about new biomarkers in AD

July 21, 2017 9:47 PM UTC

Phase II results for Probiodrug AG’s Alzheimer’s disease candidate point to potential surrogate markers for improvements in cognition that one day could be used in early development to handicap the likelihood of success in Phase III.

A major challenge in AD drug development has been the lack of biomarkers that can be easily assessed in early trials and that correlate with clinically meaningful outcomes like improvements in cognition and/or memory...

BCIQ Company Profiles

Vivoryon Therapeutics N.V.

BCIQ Target Profiles

Neurogranin (NRGN)